Please provide your email address to receive an email when new articles are posted on . A daily 30 mg dose of upadacitinib — but not the 15 mg dose — is superior to adalimumab at improving the signs ...
Please provide your email address to receive an email when new articles are posted on . He continued, “We wanted to see if it is possible to reduce the dose of adalimumab (by extending the duration ...
The US Food and Drug Administration (FDA) has approved the biosimilar adalimumab-aaty (Yuflyma) in a citrate-free, high-concentration formulation, the manufacturer, Celltrion USA, announced today. It ...
Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians ...
It is an exciting time to be a medical dermatologist, with the ongoing development of numerous safe and effective systemic treatments for several complex medical dermatologic diseases. For example, ...
The biosimilars include Hyrimoz and an unbranded version of Humira from Swiss drugmaker Novartis' (NOVN.S), opens new tab Sandoz generics division, as well as German drugmaker Boehringer Ingelheim's ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window It is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback